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Abstract
This report highlights recent insights into malarial parasite pathogenesis that are relevant for new
antimalarial drug discovery.
Introduction and context
Of the 160 or more species of Plasmodium, five are known
to infect humans, one zoonotically. Each species lives in
at least two hosts and proceeds through at least 12
distinct stages of differentiation, and formally, each
human parasite causes a different disease. Simply
elucidating the biology of human malarial parasites is
thus a huge undertaking, particularly since we can easily
culture only a handful of the distinct stages. Translating
what has been learned in the laboratory (largely via
Plasmodium falciparum blood-stage culture) into insights
relevant for understanding malaria pathogenesis is
difficult and limited in scope. Using that information
to then develop new drugs active against drug-resistant
P. falciparum, as well as P. vivax infections, is arguably the
greatest challenge in modern infectious disease.
On the bright side, we now have more genome
sequences for Plasmodium species than any other
eukaryotic genus, and along with advances in other
tools (transfection, microscopy, animal models, and
inexpensive drug-susceptibility assays) and the cellular
models of pathogenesis that can now be developed with
these tools, this bodes well for new therapeutic advances
[1–3].
Pathogenesis
Malarial pathogenesis is still not fully understood [4,5].
Hepatosplenomegaly, thrombocytopenia and anemia
usually occur as malaria develops, particularly in
children. Increasing cyclic fever, recurrent headaches,
fatigue, nausea, and musculoskeletal pain are other
clinical signs. Malarial deaths follow from coma, kidney
failure, or other complications. Hyper-reactive malarial
splenomegaly arises from an aberrant immune response
to malarial parasites and can be exacerbated via
co-infection with schistosomes or HIV [6,7]. Placental
malaria and cerebral malaria in children are not fully
understood and each presents very serious additional
clinical challenges. The cellular and molecular causes of
this wide array of clinical symptoms are complex.
Laboratory and/or animal models to determine these
causes, against which candidate drugs can be conveni-
ently screened, are severely limited, both in number and
in scope.
The initial site of parasite invasion is the skin, when
sporozoites are injected via a mosquito blood meal.
These quickly localize to the liver, invade hepatocytes,
differentiate, and divide. Very little is known about liver
stages, but new tools and approaches, particularly
intravital imaging techniques and recombinant parasites
expressing green fluorescent protein (GFP), are rapidly
defining additional key concepts [8]. Sequestration and
egress from the liver vary for different Plasmodium sp., but
for P. falciparum, new merozoites emerge within approxi-
mately 2 weeks as large clusters called merosomes. Free
merozoites are then disseminated in the blood, where a
multitude of cellular and molecular events that occur
upon red blood cell invasion have been documented and
characterized in great detail by many laboratories.
Page 1 of 4
(page number not for citation purposes)
Published: 24 February 2009
© 2009 Biology Reports Ltd
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,Major recent advances
Important complementary information on the conse-
quences of hematological changes associated with
malaria comes from biochemical and genetic studies
that have recently begun to define the underlying
molecular causes of resistance to severe malaria [9–12].
Various hemoglobinopathies have been linked to
resistance to malaria for some time, but defining the
cellular and molecular mechanisms for these phenom-
ena has proven elusive. Recently, however, one common
theme that seems to be emerging is that vascular
adhesion and rosetting defects exist for infected red
blood cells (iRBCs) from malaria patients who also carry
sickle cell or thalassemia traits [9,10]. This then re-
emphasizes that cellular adhesion phenomena are key to
malarial pathogenesis. Also, recently [13], the major
receptor for adhesion of iRBCs to the placenta during
maternal malaria was defined. It should be possible to
extend these and other advances to develop potent new
assays for drug screening.
Almost all known antimalarial drugs target the intraer-
ythrocyte stages of P. falciparum parasite development,
yet there are at least two other human stages (intrahe-
patocyte and blood gametocyte) that in theory could
also be specifically targeted. There is confusion regarding
whether known drugs [for example, chloroquine (CQ),
primaquine (PQ), and artemisinin (ART)] target multi-
ple stages, and there is also disagreement regarding how
effectively new and existing drugs act versus all impor-
tant species (for example, P. falciparum versus P. vivax).
These issues are due in part to our inability to culture all
stages effectively and the fact that P. vivax cannot be
conveniently cultured at all without constant addition of
fresh reticulocytes. Thus, currently, we have no way of
expeditiously screening for drugs that would be effective
versus multiple stages of all human malarias. Also, as
mentioned above, assays for various layers of cellular
pathogenesis are still in their infancy. This leads us to
take-home message 1: Designing versatile pharmaco-
phores or combination therapies with multiple anti-
malarial uses depends crucially on fundamental
advances in cell culture and assay design that so far
have proven elusive.
On the bright side, genome and proteome data tell us
that malarial parasites express a plethora of unique
potential molecular targets. Laboratory studies tell us
that many of these are essential to pathogenesis. Some
new target categories are well conserved across Plasmo-
dium sp. and they include unusual ion channels [14],
proteases [15], kinases [16], and metabolic pathways
[17]. Since for decades these target categories have been
the focus of more commercially lucrative drug design for
treating heart disease and cancer epidemics in Western
societies, it is possible in theory to piggy back on those
efforts to very rapidly define additional novel antimalar-
ial pharmacophores [18–20].
Take-home message 2: Coordination between academic
and pharmaceutical industry communities presents a
unique and very potent opportunity for rapid advances
in antimalarial drug discovery, particularly design of
'off-the-shelf' combination therapies.
Importantly, many of these new molecular targets have
recently been localized to unique parasite organelles,
including the acidocalcisome [21], vestigial mitochon-
drion [22], apicoplast [23], and digestive vacuole (DV)
[24,25]. These and other organelles play critical roles in
various aspects of cellular pathogenesis. Most of these
organelles are just beginning to be explored in molecular
detail, but it is already clear that they harbor a
cornucopia of unique enzymes and metabolic pathways
that in theory provide excellent drug targets.
Take-home message 3: Unique parasite organelles harbor
many excellent drug targets that remain to be capitalized
upon.
The DV has been, and remains, of primary interest since
one unique molecular target within the DV has
exquisitely important properties. Namely, free heme
released from catabolized hemoglobin (Hb) is a
principle target (but presumably not the only target
[26]) for several established, as well as new, classes of
drugs [27,28]. Mutation or alternate expression of drug
targets are major routes to drug resistance. But because
released heme is a cofactor made by the host, it cannot be
mutated by the parasite. Since there is a fixed amount of
Hb within the RBC, since the parasite must metabolize
Hb in order to survive, and since the parasite cannot
enzymatically degrade heme, the target cannot be
alternately expressed. Also, common heme-targeted
antimalarial compounds such as CQ are not broken
down by the parasite. Thus the most common and
potent routes to drug resistance are inaccessible, which
presumably is why resistance to the quintessential heme-
targeted antimalarial, CQ, took so very long to evolve on
a large scale even in the presence of massive selective
pressure. The CQ resistance (CQR) mechanism is there-
fore unique. Elucidating the CQR mechanism is begin-
ning to define additional routes to quinoline
pharmacophore modification that will provide inexpen-
sive, stable, and effective drugs [29,30].
Take-home message 4: In finding new targets in unique
organelles, we should not forget that elucidating
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to drug design in some cases.
Future directions
Promising advances in vaccine science notwithstanding,
new antimalarial drug therapies are desperately needed.
Yet relevant biochemistry, pathogenesis research, and
translational research remain underfunded. It remains to
be seen how efficiently X-omics will compete with more
traditional medicinal chemistry and pharmacology in
defining effective new treatments for malaria. To this
author, there is more than a pressing need for both
approaches. Novel drug target mining is (and must
remain) an ongoing endeavor for the medium to long
term, but with millions of deaths annually, rapid
definition of inexpensive existing drugs and drug
combinations as well as discovery of new, useful, and
inexpensive modifications of existing field-proven phar-
macophores must be accelerated.
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